Class summary at a glance.

Every drug in the Factor Xa Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $41.74Bcombined across class
Total Rx claims: 46.8M10.9M unique beneficiaries
Generic mfrs (active): 23across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Apixaban

Brand: ELIQUIS · 36.8M Part D claims (CY24) · 8.4M beneficiaries · First FDA approval: 2012-12-28

2 generic mfrs 0 plans require PA

Low NADAC$5.51

→

Avg plan cost$5.52

Part D spend $32.24B 1× spread, current vs floor

Class share

77%

of class CY24 spend

View profile →

Rivaroxaban

Brand: XARELTO · 10.0M Part D claims (CY24) · 2.5M beneficiaries · First FDA approval: 2011-07-01

17 generic mfrs 1 plans require PA

Low NADAC$0.979

→

Avg plan cost$7.68

Part D spend $9.48B 8× spread, current vs floor

Class share

23%

of class CY24 spend

View profile →

Fondaparinux

Brand: Arixtra · 20K Part D claims (CY24) · 5K beneficiaries · First FDA approval: 2011-07-14

4 generic mfrs 0 plans require PA Discontinued

Low NADAC$12.77

→

Avg plan cost$36.58

Part D spend $21.9M 3× spread, current vs floor

Class share

of class CY24 spend

View profile →

Rivaroxaban Granule

— Part D claims (CY24) · First FDA approval: 2025-09-29

Brand-only (no generics)

Low NADAC$1.96

→

Avg plan cost$1.96

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.